Use your antibodies-online credentials, if available.
Keine Produkte auf Ihrer Vergleichsliste.
Ihr Warenkorb ist leer.
Alle Spezies anzeigen
Weitere Synonyme anzeigen
Wählen Sie die Spezies und Applikation aus
anti-Human BRCA1 Antikörper:
anti-Mouse (Murine) BRCA1 Antikörper:
anti-Rat (Rattus) BRCA1 Antikörper:
Sie gelangen zu unserer vorgefilterten Suche.
Human Monoclonal BRCA1 Primary Antibody für ChIP, ICC - ABIN450350
Arizti, Fang, Park, Yin, Solomon, Ouchi, Aaronson, Lee: Tumor suppressor p53 is required to modulate BRCA1 expression. in Molecular and cellular biology 2000
Show all 9 Pubmed References
Human Monoclonal BRCA1 Primary Antibody für IHC (p), IP - ABIN445490
Bernard-Gallon, Déchelotte, Vissac, Aunoble, Cravello, Malpuech, Bignon: BRCA1 and BRCA2 protein expressions in an ovotestis of a 46, XX true hermaphrodite. in Breast cancer research : BCR 2001
Show all 8 Pubmed References
Human Polyclonal BRCA1 Primary Antibody für FACS, WB - ABIN151683
Zaugg, Su, Reilly, Moolani, Cheung, Hakem, Hirao, Liu, Elledge, Mak: Cross-talk between Chk1 and Chk2 in double-mutant thymocytes. in Proceedings of the National Academy of Sciences of the United States of America 2007
Show all 7 Pubmed References
Human BRCA1 Primary Antibody für IHC - ABIN965694
Kim, Xu, Kastan: Involvement of the cohesin protein, Smc1, in Atm-dependent and independent responses to DNA damage. in Genes & development 2002
Show all 5 Pubmed References
Human Polyclonal BRCA1 Primary Antibody für IHC - ABIN965696
Arlt, Xu, Durkin, Casper, Kastan, Glover: BRCA1 is required for common-fragile-site stability via its G2/M checkpoint function. in Molecular and cellular biology 2004
Show all 5 Pubmed References
Human Monoclonal BRCA1 Primary Antibody für CyTOF, FACS - ABIN152030
Okada, Ouchi: Cell cycle differences in DNA damage-induced BRCA1 phosphorylation affect its subcellular localization. in The Journal of biological chemistry 2003
Show all 4 Pubmed References
Human Monoclonal BRCA1 Primary Antibody für ICC, FACS - ABIN152032
Martin, Nahas, Tunuguntla, Fike, Gatti: Assessing 'radiosensitivity' with kinetic profiles of γ-H2AX, 53BP1 and BRCA1 foci. in Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2011
Show all 4 Pubmed References
Human Monoclonal BRCA1 Primary Antibody für ChIP, ICC - ABIN151868
Li, Ting, Zheng, Chen, Ziv, Shiloh, Lee, Lee: Functional link of BRCA1 and ataxia telangiectasia gene product in DNA damage response. in Nature 2000
Show all 3 Pubmed References
Polyclonal BRCA1 Primary Antibody für IF - ABIN4948304
Scully, Livingston: In search of the tumour-suppressor functions of BRCA1 and BRCA2. in Nature 2000
Show all 3 Pubmed References
Human Polyclonal BRCA1 Primary Antibody für IP, PLA - ABIN151492
Rusin, Zajkowicz, Butkiewicz: Resveratrol induces senescence-like growth inhibition of U-2 OS cells associated with the instability of telomeric DNA and upregulation of BRCA1. in Mechanisms of ageing and development 2009
Show all 2 Pubmed References
Data indicate there was high genetic correlation between risk of estrogen receptor (ER (zeige ESR1 Antikörper))-negative breast cancer and breast cancer risk for BRCA1 mutation carriers.
BRCA1 was methylated in 9.33% of breast tumors and was associated with lymphatic metastasis.
Our results provide novel insights regarding the physician-patient interaction and the organizational aspects of the health-care system that may significantly impact the cancer screening practices of BRCA1/2 noncarriers.
Germline BRCA1/2 gene mutations could result in genomic instability and an elevated gene mutation rate (such as the p53 (zeige TP53 Antikörper) gene) in breast luminal cells compared with the general population, predisposing BRCA carriers to develop p53 (zeige TP53 Antikörper)-positive/triple-negative breast carcinomas.
Data suggest that locus-specific LOH may be a clinically useful biomarker to predict primary resistance to DNA damaging agents in patients with germline BRCA1 and BRCA2 (zeige BRCA2 Antikörper) mutations.
Our findings suggest that BRCA1 exons 1-2 deletion and exons 21-24 deletion should be included in the recurrent BRCA1/2 mutations panel for genetic testing of high-risk Pakistani breast/ovarian cancer patients.
we saw no increased risk of cardiotoxicity among breast cancer patients with BRCA1 and/or BRCA2 (zeige BRCA2 Antikörper) gene mutations treated with standard doses of anthracycline compared to the general population.
This is the largest study of comprehensive BRCA testing(BRCA1 and BRCA2 (zeige BRCA2 Antikörper)) among Brazilians to date. Several criteria that are not included in the NCCN achieved a higher predictive value. Identification of the most informative criteria for each population will assist in the development of a rational approach to genetic testing
Data show a consistent NFkappaB hyperactivity associated with BRCA1 dysfunction as a consequence of increased reactive oxygen species (ROS) in a subset of BRCA1-mutant and triple negative breast cancer.
We performed the genotyping of the polymorphisms BRCA1/P871L and BRCA1/Q356R by Polymerase Chain Reaction-Restriction Fragment Length Polymorphism, and of variant allele BRCA2 (zeige BRCA2 Antikörper)/N372H through direct sequencing.
Investigation on BRCA1 SNPs and its effects on mastitis in Chinese commercial cattle.
The gene-specific SNP marker analysis showed a significant association of BRCA1 C28300A with milk somatic cell scores.
In general, OC use, childbearing and breastfeeding do not differ between BRCA1/2 carriers and non-carriers with ovarian cancer. However, the effects of tubal ligation may differ between BRCA1 carriers and non-carriers.
Bovine BRCA1 was phosphorylated and nuclear speckling was enhanced in response to DNA-damaging agents.These results provide evidence that phosphorylation and nuclear relocalization are highly conserved features of the BRCA1 response to genotoxic stress.
Consensus-based recombinant adeno-associated virus-BRCA1 knock out virus vectors failed to induce BRCA1 knockout in Gottingen fibroblasts.
TGFbeta (zeige TGFB1 Antikörper) stabilized the abundance of BRCA1 by reducing the abundance of microRNA-182 (miR (zeige MLXIP Antikörper)-182). Ectopic expression of BRCA1 or antagonism of miR (zeige MLXIP Antikörper)-182 in cultured TGFbeta (zeige TGFB1 Antikörper)-deficient mammary epithelial cells restored luminal lineage commitment.
BRCA1 inactivation can increase expression of miR (zeige MLXIP Antikörper)-155, contributing to cardiac hypertrophy. And Rev produces their beneficial effects partially by down-regulating miR (zeige MLXIP Antikörper)-155 expression, which might be a novel strategy for treatment of cardiac hypertrophy.
both murine Brca1185stop tumors and human BRCA1185delAG breast cancer cells express a new gene domain-less (RING-less) BRCA1 protein that mediated resistance to homologous recombination deficient-targeted therapies
Genomic instability can be rescued by deletion of Trp53bp1 (zeige TP53BP1 Antikörper), encoding the DNA damage response factor 53BP1 (zeige TP53BP1 Antikörper); mice expressing RING-less BRCA1 do not show an increased susceptibility to tumors in the absence of 53BP1 (zeige TP53BP1 Antikörper); Genomic instability in cells expressing RING-less BRCA1 correlates with loss of BARD1 (zeige BARD1 Antikörper) and a defect in restart of replication forks after hydroxyurea treatment
the aberrant proliferative capacity of Brca1(-/-) luminal progenitor cells is linked to the replication-associated DNA damage response, where proliferation of mammary progenitors is perpetuated by damage-induced, autologous NF-kappaB (zeige NFKB1 Antikörper) signaling.
We report here elevated recombination rates at telomeres in cells from human BRCA1 mutation carriers and in mouse embryonic stem cells lacking both copies of functional Brca1.
loss of Brca1, a tumor suppressor that functions in DNA damage repair, in the mammary epithelium induced senescence with induction of p16 (zeige CDKN2A Antikörper) and a decline of stem cell function, which was rescued by p16 (zeige CDKN2A Antikörper) loss.
Brca1-Wwox (zeige WWOX Antikörper) interaction supports non-homologous end-joining as the dominant DSB repair pathway in Wwox (zeige WWOX Antikörper)-sufficient cells
Structure-guided separation-of-function mutations show that the RNF8 E2 stimulating activity is essential for DSB signaling in mammalian cells and is necessary for downstream recruitment of 53BP1 and BRCA1.
Results reveal a broader biological role for BRCA1 in protecting the developing embryo from oxidative stress, and corroborate a role for DNA damage in the mechanism of ethanol embryotoxicity.
MRN (Mre11 (zeige MRE11A Antikörper), Rad50 (zeige RAD50 Antikörper), and Nbs1 (zeige NLRP2 Antikörper)) complex, CtIP (zeige RBBP8 Antikörper), and BRCA1 are required for both the removal of Top2 (zeige TOP2 Antikörper)-DNA adducts and the subsequent resection of Top2 (zeige TOP2 Antikörper)-adducted DSB ends.
BRCA1-dependent helicase (zeige DNA2 Antikörper) unloading is a critical, early event in DNA interstrand crosslink repair.
This gene encodes a nuclear phosphoprotein that plays a role in maintaining genomic stability, and it also acts as a tumor suppressor. The encoded protein combines with other tumor suppressors, DNA damage sensors, and signal transducers to form a large multi-subunit protein complex known as the BRCA1-associated genome surveillance complex (BASC). This gene product associates with RNA polymerase II, and through the C-terminal domain, also interacts with histone deacetylase complexes. This protein thus plays a role in transcription, DNA repair of double-stranded breaks, and recombination. Mutations in this gene are responsible for approximately 40% of inherited breast cancers and more than 80% of inherited breast and ovarian cancers. Alternative splicing plays a role in modulating the subcellular localization and physiological function of this gene. Many alternatively spliced transcript variants, some of which are disease-associated mutations, have been described for this gene, but the full-length natures of only some of these variants has been described. A related pseudogene, which is also located on chromosome 17, has been identified.
BRCA1/BRCA2-containing complex, subunit 1
, RING finger protein 53
, breast and ovarian cancer susceptibility protein 1
, breast and ovarian cancer sususceptibility protein 1
, breast cancer type 1 susceptibility protein
, protein phosphatase 1, regulatory subunit 53
, BRCA1 homologue
, breast cancer type 1 susceptibility protein homolog
, breast cancer 1, early onset
, BRCA1 homolog
, breast and ovarian cancer susceptibility protein
, breast cancer associated 1